Redemplo Wins FDA Nod: A New Chapter for Familial Chylomicronemia Syndrome Care https://t.co/D6aLhVStVn Read now at https://t.co/pYPVOJiweA #PatientWorthy #FamilialChylomicronemiaSyndrome #FCS #Redemplo

🧬 FDA has approved Redemplo (plozasiran) a new siRNA therapy for familial chylomicronemia syndrome (FCS), a rare genetic disorder that causes dangerously high triglyceride levels and increases the risk of acute pancreatitis. 👉 Read: 🔗 https://t.co/B82XwPNOMF #BiotechNews

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China - For More Information Visit https://t.co/FBSenGs8EV @ArrowheadPharma #FCS #Rare_Diseases #Familial_Chylomicronemia_Syndrome #OrphanDrugs

FDA approves Redemplo (plozasiran) — the first therapy for familial chylomicronemia syndrome (FCS). Clinical trial results: 59% reduction in triglycerides by month 10. #FDA #Redemplo #FCS #RareDisease #Biotech #Healthcare #MedicalNews #Pancreatitis https://t.co/IE5AY4fq1R

FDA Approves REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS)

$ARWR - Arrowhead Pharmaceuticals has gained FDA approval for REDEMPLO (plozasiran), the first treatment for adults with familial chylomicronemia syndrome. Read more on https://t.co/wZbB4h5XW2

Plozasiran (Redemplo), an siRNA therapy targeting apoC-III, has been FDA-approved to lower triglycerides in adults with familial chylomicronemia syndrome. Read more using the link in the replies below.

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome - For More Information Visit https://t.co/0WEOnds4F5 @ArrowheadPharma #FDA #FCS #Familial_Chylomicronemia_Syndrome

#WCIRDC2025 Excellent presentation by @YHandelsmanMD on Redemplo from @ArrowheadPharma which was just approved for FCS. ➡️ SiRNA therapy ➡️ Mean baseline trig in PALISADE was 2311 mg/dl ➡️ 80% reduction in trigs that was maintained ➡️ Q3 months @WCIRDC @GoHealio @HeartinDiabetes

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China https://t.co/rUrFMo2M8D $ARWR

$ARWR +10.56% today Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China More Info: https://t.co/RJeN6CqT8P

FDA approves Redemplo (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome - Arrowhead https://t.co/P2NAZwv0yZ

$arwr REDEMPLO is the first and only FDA-approved siRNA medicine for people living with FCS and can be self-administered at home with a simple subcutaneous injection once every three months. One less iron in the fire $ions

The FDA has approved Redemplo, which showed an 83% reduction in acute pancreatitis risk and significant triglyceride reduction https://t.co/kytEnzGXdb

Breaking news: Health Canada has approved our therapy as an adjunct to diet to lower triglycerides in adults with Familial Chylomicronemia Syndrome (FCS) where standard triglyceride-lowering therapies were inadequate. Learn more: https://t.co/5CbABFbf49 #RareDisease #ForFCS

Plozasiran (APOC3 siRNA, REDEMPLO) is now FDA-approved as an adjunct to diet to reduce triglycerides among patients with familial chylomicronemia syndrome. And congrats to @ArrowheadPharma on their first FDA-approved medicine! https://t.co/CuySHde1q8

$IONS how does Ionis still have a bid? REDEMPLO is safer, more effective, at home dosing, every three months instead of monthly and a fraction of the price of Tryngolza. $ARWR

Arrowhead rises as FDA approves lead drug for rare disorder Shares of Arrowhead Pharmaceuticals (ARWR) gained on Tuesday after the U.S. FDA approved its lead asset Redemplo (plozasiran) for adults with a rare genetic disorder called familial ... https://t.co/qWeUDcts1v

Arrowhead Pharmaceuticals (NASDAQ: $ARWR) has secured Health Canada approval for Redemplo (plozasiran), an siRNA therapy to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). Redemplo is now the first and only siRNA medicine approved in Canada for this